Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 5/20 | 0.47 |
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | GPR183 | P32249 | 6/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20154563 | 0.87 | NNMT (0.47) | RETNNMTGPR183MGLLKCNH2 | |
| SCHEMBL20148719 | 0.84 | HRH3 (0.44) | RETNNMTGPR183MGLLKCNH2 | |
| SCHEMBL23555184 | 0.80 | RET (0.41) | RETNNMTGPR183MGLLKCNH2 | |
| SCHEMBL20160459 | 0.79 | RET (0.48) | RETGPR183TACR3 | |
| SCHEMBL23555183 | 0.78 | GPR183 (0.42) | RETNNMTGPR183MGLLKCNH2 | |
| SCHEMBL18713231 | 0.77 | NNMT (0.49) | RETNNMTGPR183MGLLKCNH2 | |
| SCHEMBL20071400 | 0.76 | NNMT (0.43) | RETNNMTGPR183MGLLKCNH2 | |
| SCHEMBL18390346 | 0.74 | NNMT (0.49) | RETNNMTGPR183MGLLKCNH2 | |
| SCHEMBL20962681 | 0.74 | NNMT (0.46) | RETNNMTGPR183MGLLKCNH2 | |
| SCHEMBL18390347 | 0.74 | NNMT (0.46) | RETNNMTGPR183MGLLKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885NNMT 2639/4885GPR183 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.